Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes

Zampetaki, Anna; Kiechl, Stefan; Drozdov, Ignat; Willeit, Peter; Mayr, Ursula; Prokopi, Marianna; Mayr, Agnes; Weger, Siegfried; Oberhollenzer, Friedrich; Bonora, Enzo; Shah, Ajay M.; Willeit, Johann; Mayr, Manuel

doi:10.1161/circresaha.110.226357

Cited by 1,308 publications

(1,210 citation statements)

References 41 publications

Supporting

Mentioning

1,095

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in one study miR-192 and miR-193b were reported to be deregulated in the serum of prediabetic individuals but not in that of diabetic individuals, suggesting that prediabetic, diabetic and healthy individuals have distinct profiles [26]. Finally, altered miRNA expression (miR-15a, -29b, -126, -223, -28-3p) has been observed in serum from normoglycaemic individuals who developed type 2 diabetes over a 10 year period [27]. While additional investigations are clearly needed to strengthen these findings, the results are promising, as circulating miRNAs could be early predictive biomarkers of type 2 diabetes and could help to distinguish healthy individuals from prediabetic and diabetic patients.…”

Section: Circulating Mirnas As Early Predictive Biomarkers Of Diabetesmentioning

confidence: 97%

“…The observation of the deregulation of miRNA profiles in different biological fluids of diabetic patients compared with healthy controls was the first evidence supporting the idea that miRNAs could be biomarkers of the diabetic disease (Table 1). Indeed, a differential miRNA profile between type 2 diabetic patients and healthy controls was found in whole blood [20,21], serum [22][23][24][25][26], plasma [27][28][29][30][31][32][33] and plasma exosomes [34]. Studies revealed a different miRNA pattern in serum of type 1 diabetic patients compared with healthy individuals [35], as well as in plasma [36,37] and urine [36].…”

Section: Circulating Mirnas As Biomarkers Of the Diabetic Conditionmentioning

confidence: 99%

“…Several studies have recommended plasma miRNAs as potential biomarkers of peripheral artery complications in type 2 diabetic patients [27,32]. Among them, miR-126 is expressed in endothelial cells and hence is enriched in highly vascularised tissues such as the heart.…”

Section: Circulating Mirnas As Biomarkers To Assess Diabetic Complicamentioning

confidence: 99%

See 2 more Smart Citations

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

The explosive increase in the worldwide prevalence of diabetes over recent years has transformed the disease into a major public health concern. While diabetes can be screened for and diagnosed by reliable biological tests based on blood glucose levels, by and large there are no means of detecting at-risk patients or of following diabetic complications. The recent discovery that microRNAs are not only chief intracellular players in many biological processes, including insulin secretion and action, but are also circulating, has put them in the limelight as possible biological markers. Here we discuss the potential role of circulating microRNAs as biomarkers in the context of diabetes and its associated complications.

show abstract

Section: Circulating Mirnas As Early Predictive Biomarkers Of Diabetesmentioning

confidence: 97%

Section: Circulating Mirnas As Biomarkers Of the Diabetic Conditionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Type 2 DM has been associated with decreased endothelial cell expression of microRNA‐126 49. Stroke in type 2 DM mice significantly decreases microRNA‐126 expression in blood serum and ischemic brain tissue compared to non‐DM stroke mice 17.…”

Section: Cell‐based Therapies and Exosome Therapy For Diabetic Strokementioning

confidence: 99%

Cell-Based and Exosome Therapy in Diabetic Stroke

Venkat

Chopp

Chen

2018

Stem Cells Translational Medicine

View full text Add to dashboard Cite

SummaryStroke is a global health concern and it is imperative that therapeutic strategies with wide treatment time frames be developed to improve neurological outcome in patients. Patients with diabetes mellitus who suffer a stroke have worse neurological outcomes and long‐term functional recovery than nondiabetic stroke patients. Diabetes induced vascular damage and enhanced inflammatory milieu likely contributes to worse post stroke outcomes. Diabetic stroke patients have an aggravated pathological cascade, and treatments that benefit nondiabetic stroke patients do not necessarily translate to diabetic stroke patients. Therefore, there is a critical need to develop therapeutics for stroke specifically in the diabetic population. Stem cell based therapy for stroke is an emerging treatment option with wide therapeutic time window. Cell‐based therapies for stroke promote endogenous central nervous system repair and neurorestorative mechanisms such as angiogenesis, neurogenesis, vascular remodeling, white matter remodeling, and also modulate inflammatory and immune responses at the local and systemic level. Emerging evidence suggests that exosomes and their cargo microRNA mediate cell therapy derived neurorestorative effects. Exosomes are small vesicles containing protein and RNA characteristic of its parent cell. Exosomes are transported by biological fluids and facilitate communication between neighboring and remote cells. MicroRNAs, a class of naturally occurring, small noncoding RNA sequences, contained within exosomes can regulate recipient cell's signaling pathways and alter protein expression either acting alone or in concert with other microRNAs. In this perspective article, we summarize current knowledge and highlight the promising future of cell based and exosome therapy for stroke and specifically for diabetic stroke. stem cells translational medicine 2018;7:451–455

show abstract

“…Dans ce type de situation, l'augmentation de certains miARN dans le sérum n'est donc qu'une conséquence indirecte de la pathologie, alors que dans d'autres cas, les miARN pourraient avoir un rôle pathogénique et participer à l'évolution de la maladie. Dans le diabète de type 2 par exemple, une modification des quantités sériques de plusieurs miARN, dont miR-126, miR-223 et miR-15a, est détectée avant même le développement de la maladie, ce qui suggère fortement l'implication directe de ces miARN dans la mise en place de la physiopathologie diabétique [31,38]. of cancer greatly increases the chances for successful treatment, the identification of accurate biomarkers is essential.…”

Section: Des Régulateurs Paracrinesunclassified